NCT07476001 2026-03-17
Phase 2a Study of High-Dose Testosterone Followed by Radioligand Therapy in mCRPC
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Recruiting
Clinical Trials
18 trialsNCT06909825 2026-03-05
FPI-2265 (225Ac-PSMA-I&T) and Olaparib for Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Fusion Pharmaceuticals Inc.
Phase 2 Active not recruiting
NCT06533644 2026-02-27
A Study of SYNC-T Therapy SV-102 in Participants With Metastatic Castration-Resistant Prostate Cancer
Syncromune, Inc.
Phase 2 Recruiting
NCT04754191 2026-02-12
ENCORE
University of Utah
Phase 2 Active not recruiting
NCT06866938 2026-01-06
ReaLuP
Hospices Civils de Lyon
Phase 2 Recruiting
NCT06228053 2025-12-22
SYNERGY-201
Syntrix Biosystems, Inc.
Phase 2 Recruiting
NCT06568562 2025-12-09
PRO-XL
University of Utah
Phase 2 Recruiting
NCT06029998 2025-11-28
BORXPTEN
University of Utah
Phase 2 Recruiting
NCT06100705 2025-11-04
Sipuleucel-T Combined With Bipolar Androgen Therapy in Men With mCRPC
Yale University
Phase 2 Recruiting
NCT06402331 2025-10-09
AlphaBreak
Fusion Pharmaceuticals Inc.
Phase 2 Recruiting
NCT04158245 2025-09-22
18F-fluciclovine PET in Metastatic Castration Resistant Prostate Cancer Treated With Life Prolonging Therapies
Tulane University
Phase 2 Completed
NCT06401980 2025-08-14
Darolutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Swiss Cancer Institute
Phase 2 Recruiting
NCT03770455 2024-07-09
Avelumab Plus 2nd-generation ADT in African American Subjects With mCRPC
Tulane University
Phase 2 Terminated
NCT05762536 2024-06-27
DAROTAXEL
Erasmus Medical Center
Phase 2 Recruiting
NCT05955209 2023-07-21
Clinical Study on the Efficacy and Safety of RC48-ADC in the Treatment of Metastatic Castration Resistant Prostate Cancer (mCRPC)
Peking University Cancer Hospital & Institute
Phase 2 Unknown
NCT04676607 2023-06-13
SHR7390 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 2 Completed
NCT05327621 2022-04-14
Pamiparib in mCRPC With HRD or BRCA1/2 Mutation
Sun Yat-sen University
Phase 2 Unknown
NCT04586543 2020-10-14
Clinical Trial of Selegiline Plus Docetaxel for the Treatment of Metastatic, Castrate-resistant Prostate Adenocarcinoma
University of Pecs
Phase 2 Unknown